KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Multiple previous studies reported associations between the NKG2D SNP and clinical outcome in malignancy.26–28 41 For example, Hara et al observed that patients with chronic myeloid leukemia carrying NKG2D high natural cytotoxicity alleles achieved deeper molecular remission more quickly after receiving dasatinib.27 Similar results were reported in a survival analysis of different types of leukemia.26 The results presented in this study point to the possibility that such effects are instead driven by NKG2A variants.